Disorders of potassium homeostasis can potentiate the already elevated risk of arrhythmia in heart failure. Heart failure patients have a high prevalence of chronic kidney disease, which further heightens the risk of hyperkalemia, especially when renin-angiotensin-aldosterone system inhibitors are used. Acute treatment for hyperkalemia may not be tolerated in the long term. Recent data for patiromer and sodium zirconium cyclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have sparked interest in the treatment of hyperkalemia, as well as the potential use of renin-angiotensin-aldosterone system inhibitors in patients who were previously unable to take these drugs or tolerated only low doses. This review discusses the epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure; provides an overview of traditional and novel ways to approach management of hyperkalemia; and discusses the need for further research to optimally treat heart failure. (J Am Coll Cardiol 2016;68:1575-89) 
H yperkalemia can be life threatening because of the associated risk for arrhythmias and conduction system abnormalities (1, 2) . Generally, a serum potassium level higher than 5.0 mmol/l is defined as hyperkalemia (1) . Among patients hospitalized for any cause, the prevalence of hyperkalemia has been estimated at 1% to 10% (3) . Patients with chronic kidney disease (CKD), heart failure (HF), and diabetes mellitus and those using renin-angiotensin-aldosterone system inhibitors (RAASi) are at 2 to 3 times higher risk for hyperkalemia (4) (5) (6) . In hospitalized patients admitted with worsening HF, despite aggressive diuresis, increases in serum potassium levels are observed (7) . With growing numbers of CKD and HF patients taking RAASi and mineralocorticoid receptor antagonists (MRAs), hyperkalemia has become a more common concern. Angiotensin-converting enzyme inhibitors (ACEi), angiotensin-receptor blockers (ARBs), and
MRAs have proven benefit in patients who are also
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at high risk for hyperkalemia (8) . Even more challenging is the fact that many patients have several of these comorbidities simultaneously and are attempting to use 1 or more RAASi together. Thus, many patients in need for these therapies are unable to tolerate them, or if these medicines are prescribed, they are prescribed at less than optimal dosages. RAASi discontinuation for hyperkalemia represents an undesirable clinical compromise. Importantly, many clinical trials have excluded patients with advanced CKD and those with or at risk for hyperkalemia, leaving a critical evidence gap in pharmacotherapy for these high-risk patients.
POTASSIUM HOMEOSTASIS
Under normal circumstances, the kidneys are responsible for excreting 90% of the potassium that is consumed daily (9) . Most of the potassium is freely Secretion of potassium by the collecting duct is regulated by the serum aldosterone and sodium concentration in the distal tubule (11) . Aldosterone is regulated by the renin-angiotensin-aldosterone system (RAAS) and by serum potassium levels (13). In HF, when the renal perfusion pressure falls, juxtaglomerular cells secrete renin, which converts angiotensinogen to angiotensin II, in conjunction with angiotensin-converting enzyme (ACE) (14) .
Angiotensin II acts on zona glomerulosa of the adrenal glands and stimulates aldosterone secretion. High serum potassium is also a stimulator of aldosterone, which lowers serum potassium by stimulating potassium excretion from distal tubule (13,15).
Increased potassium intake increases kaliuresis, and it is postulated that potassium receptors also reside in gastrointestinal tract, enterohepatic circulation, and liver (12) . A role for the pituitary gland in potassium homeostasis has been shown in rats where renal potassium excretion was impaired post-hypophysectomy (16, 17) . In human subjects, hourly increased renal and gastrointestinal potassium excretion after 35 mmol of oral potassium persisted following aldosterone blockade, suggesting a gastrointestinal-renal kaliuretic signaling axis that is independent of the changes in serum potassium concentration and aldosterone (18) .
HYPERKALEMIA IN PATIENTS WITH HF: ROLE OF RENAL DISEASE AND THERAPY
Approximately 26 million people globally have HF (19) . In addition, excess dietary intake of foods high in potassium or sodium supplements containing high potassium content can cause hyperkalemia (22) (23) (24) ( Figures 2 and 3) . MRAs or RAASi increase the risk of hyperkalemia (25) . As the use of RAASi has increased, especially in higher doses and in combination (26) (27) (28) (29) , hyperkalemia has become more common. mmol/l, respectively; p < 0.001), a higher mortality risk was observed when potassium levels increased to more than 5.5 mmol/l in the spironolactone group (34) . The beneficial effect of spironolactone compared with placebo was maintained at all levels of hyper-or hypokalemia, showing a U-shaped relationship between potassium levels and mortality, with higher mortality rates in patients randomized to placebo at all potassium levels (p < 0.0001) (34) . The use of spironolactone increased after the RALES trial; however, the hospitalizations attributed to hyperkalemia also increased to 11 of 1,000 patients in 2001 compared with 2.4 of 1,000 patients in 1994 (p < 0.001) (8) .
Additionally, the rate of in-hospital hyperkalemiaassociated death in HF patients increased from 0.10 of 1,000 patients in 1994 to 0.39 of 1,000 patients in 2001
(p < 0.001) (8) . These data underscore both the importance of hyperkalemia when augmenting RAASi and the need for careful monitoring of electrolytes.
Hyperkalemia risk is increased with concomitant CKD in HF patients. In 105,388 HF patients enrolled in the ADHERE (Acute Decompensated Heart Failure National Registry) study, more than 60% of patients had kidney disease (35) . In patients with CKD, the prevalence of hyperkalemia can be up to 20% and is 
Heart Failure Diabetes
Prevalence of heart failure and diabetes mellitus may increase the risk of hyperkalemia on the basis of disease and concomitant therapies. 
CURRENT MANAGEMENT OF HYPERKALEMIA
The treatment of hyperkalemia depends on the severity and cause ( Table 1 ).
EMERGENT MANAGEMENT. In patients with electrocardiographic changes and/or potassium levels >7.0 mmol/l, intravenous calcium is administered to prevent arrhythmia (41) . To rapidly lower potassium levels, insulin and beta-2 adrenoreceptor agonists are used to redistribute potassium from the extracellular to the intracellular space; however, this is a temporary measure (11) . 
Hyperkalemia in HF promoting the development of resistance to already reduced RAASi-induced aldosterone levels (11,13).
Many of the diseases that affect tubular function also impair the release of renin and result in hyporeninemic hypoaldosteronism and impaired tubular function (11) .
NEW TREATMENTS FOR HYPERKALEMIA
Sodium polystyrene sulfonate has significant limitations for chronic use and has not been evaluated in large randomized trials (48) (49) (50) . Its use in HF is limited, as it may worsen edema by exchanging sodium for potassium ions (51) . In addition, it is poorly tolerated and associated with severe and even fatal gastrointestinal complications (50, 52) . In a small single-center Sarwar et al.
conditions in the colon, where increased potassium secretion through big potassium channels represents an adaptive response to elevated serum potassium (59) . Hypomagnesemia is reported in clinical trials of patiromer; however, there were no significant neuromuscular or cardiac abnormalities noted with treatment (56, (60) (61) (62) .
CLINICAL TRIALS WITH PATIROMER (RLY5016).
Patiromer has been evaluated in 3 clinical trials ( Table 3 ). This figure shows the advantages, concerns, and clinical scenarios that have been tested and those that need to be addressed with patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalemia in heart failure population. RAASi ¼ renin-angiotensin aldosterone system.
Hyperkalemia in HF hyperkalemia groups resulted in a reduction from baseline level at 4 weeks, which was maintained through 52 weeks. It is important to note that in both the OPAL-HK and the AMETHYST-DN trials, patients were able to maintain RAASi therapy.
E f fi c a c y i n H F . A subgroup analysis of the OPAL-HK
trial studied the effects of patiromer in HF patients (63) . Of the 102 patients in the first 4 weeks, 76% achieved a serum potassium level of 3.8 mmol/l to 5.0 mmol/l. In the second withdrawal phase, hyperkalemia occurred in 52% (n ¼ 22) of patients taking placebo and 8% (n ¼ 27) of those taking patiromer (p <
0.001). The PEARL-HF (Evaluation of Patiromer in
Heart Failure Patients) trial studied patiromer in patients with chronic HF (56) . Patients either had eGFR <60 ml/min or a history of hyperkalemia resulting in discontinuation of a RAASi. A total of 155 patients were started on 25 mg/day of spironolactone and were randomized to double-blind treatment with 30 g/day of patiromer or placebo for 4 weeks. At 4 weeks, the patiromer treatment group had lowered potassium levels (7.3% vs. 24.5%, respectively; p ¼ 0.015) and was more likely to have spironolactone increased to 50 mg/day (91% vs. 74%, respectively; p ¼ 0.019).
S a f e t y a n d t o l e r a b i l i t y . The most common side effect in the initial phase of the OPAL-HK trial was constipation (11%), followed by diarrhea (8%), hypomagnesemia (8%), and hypokalemia (3%). Magnesium replacement therapy was initiated in 4% of subjects during the initial phase. In the withdrawal phase, constipation, diarrhea, and nausea (4% each)
were the most common gastrointestinal events reported with patiromer, whereas these events occurred in none of the patients with placebo (63). In the PEARL-HF trail, the most common adverse events were gastrointestinal complaints (12%, n ¼ 21: flatulence, diarrhea, constipation, or vomiting) (56).
Hypokalemia is an important concern in HF (64).
When used as preventive measure for hyperkalemia, patiromer in PEARL-HF resulted in hypokalemia (<3.5 mmol/l) in 6% of patients versus 0% of placebo patients (p ¼ 0.094) (56) . In addition, hypomagnesemia (<1.8 mg/dl) was observed in 24% of the patients in the treatment group versus 2.1% in the placebo group. Adverse events resulting in patient withdrawal were similar in both groups (56) .
DRUG-DRUG INTERACTION WITH PATIROMER.
Initial in vitro study data showed patiromer binding of >30% in 14 of 28 drugs tested, including 30% to 50% binding to clopidogrel, furosemide, metformin, warfarin, metoprolol, verapamil, and lithium, whereas there was >50% binding to amlodipine, cinacalcet, ciprofloxacin, levothyroxine, quinidine, thiamine, and trimethoprim (65) . In addition, a 30% reduction was seen in the availability of valsartan and rosiglitazone in preclinical coadministration studies in rats (56) . Of 14 drugs tested initially for drug-drug interactions, 12 were tested in healthy volunteers (phase 1) in randomized, open-label studies, using a 3-way crossover design, according to FDA recommendations. The results released by the manufacturer showed no clinically meaningful reduction in absorption and no impact on peak concentration (C max ) of lithium, trimethoprim, verapamil, and warfarin. There was also no clinically meaningful reduction in absorption, although there was some reduction in C max , of amlodipine, cinacalcet, clopidogrel, furosemide, and metoprolol and reduced absorption and C max of ciprofloxacin, levothyroxine, and metformin. Quinidine and thiamine were not tested (66) . Meanwhile, the manufacturer, on the basis of in vitro studies, recommends taking these medications at least 6 h before or 6 h after patiromer, whereas the data from in vivo studies are being reviewed by the FDA (67).
SODIUM ZIRCONIUM CYCLOSILICATE
Sodium zirconium cyclosilicate (ZS-9) is an inorganic, orally administered potassium-binding compound that has recently been investigated in phase II and III clinical trials. STRUCTURE AND MECHANISM OF ACTION. ZS-9 is administered as a once-daily dose, and its physiological ion channels filter ions on the basis of their differing diameters. ZS-9 has a structure that mimics physiological potassium channels and selectively captures potassium cations. This is accomplished by the use of a selectivity filter (62) . In order to pass through the channel, an ion must shed its hydration Table 1 .
Hyperkalemia in HF sphere and only then can it interact with the carbonyl oxygens in the channel. Both sodium and potassium are of the size that would fit in the ZS-9 structure ring, but after shedding their hydration shells, only K þ has a size sufficient to fit into the ZS-9 pore size (68) ( Figure 5 ).
ZS-9 is not absorbed in the gastrointestinal tract
and is available as insoluble, free-floating, odorless, tasteless, white crystalline powder. It is an inorganic compound, unlike sodium polystyrene sulfonate, and specifically traps monovalent (potassium and ammonium) over divalent cations (like Ca  2þ or Mg   2þ ).
Because it is not systemically absorbed, the risk of systemic toxicity is low (69) (70) (71) . The potassium exchange capacity of ZS-9 was studied using a simulated gastrointestinal tract medium with various concentrations of ZS-9 doses and medium pH (68) . It was observed that in the simulated gastric fluid (pH w1.2),
there is an initial drop in potassium concentration, which reverses soon afterward. In the small intestine (pH w4.5), there is an immediate uptake of potassium, followed by a small release, with equilibrium reached in approximately 20 min. In the large intestine (pH 6.8), there is a rapid uptake of potassium during the first 10 min, followed by continued but slower uptake over the next hour with no further increase thereafter. It was also observed that the binding capacity of ZS-9 increased proportionately with increasing concentration >0.5 to 50 mg/ml. These results led to the conclusion that, in environments mimicking the human gastrointestinal tract and in the presence of ZS-9, potassium equilibrium was reached relatively quickly (<20 min) (68) . Mg 2þ after shedding its water coat has a diameter of 1.44 A (72).
This diameter is energetically unfavorable for Mg þ2 to interact with the oxygen bonds in the ZS-9 structural ring (68).
CLINICAL TRIALS WITH ZS-9. Sodium zirconium cyclosilicate has been evaluated in 4 clinical trials ( Table 4 ). The ZS-9 pore is shown with a potassium ion (A), a sodium ion (B), and a calcium ion (C). The specificity for potassium is likely due to the size and binding sites of the pores. Adapted with permission from Stavros et al. (68) . Abbreviations as in Figures 1 and 4 .
Sarwar et al. Table 4) . In the open-label phase, mean K þ levels decreased from 5.6 to 4.5 mmol/l at 48 h. Median time to normalization was 2.2 h, 84% achieved normokalemia by 24 h and 98% by 48 h. In the randomized phase, K þ level declined though days 8-29 with all ZS-9 doses vs. placebo (4.8 mmol/l, 4.5 mmol/l, and 4.4 mmol/l for 5 g, 10 g, and 15 g, respectively; 5.1 mmol/l for placebo. The proportion of patients with mean K þ <5.1 mmol/l during days 8-29 was higher in all treatment groups vs. placebo (80%, 90%, and 94% for the 5-, 10-, and 15-g groups, respectively, vs. 46% with placebo. Edema was more common in the ZS-9, 15-g group (2%, 2%, 6%, and 14% in placebo, 5-g, 10-g, and 15-g groups, respectively). Hypokalemia developed in 10% and 11% in the 10-g and 15-g treatment groups, respectively, vs. none in the 5-g or placebo group. In the randomized phase, despite constant RAASi doses, K þ level declined though days 8-29 with all ZS-9 doses vs. placebo (4.7 mmol/l, 4.5 mmol/l, and 4.4 mmol/l for 5 g, 10 g, and 15 g, respectively; 5.2 mmol/l for placebo. The proportion of patients with mean K þ <5.1 mmol/l during days 8-29 was higher in all treatment groups vs. placebo (83%, 89%, and 92% for the 5-g, 10-g, and 15-g dose groups, respectively, vs. 40% with placebo. Edema was more common in the maintenance phase, occurring in 1, 2, and 5 patients in the 5-g, 10-g, and 15-g dose groups, respectively, vs. 1 patient in the placebo group.
eGFR ¼ estimated glomerular filtration rate; HARMONIZE ¼ Hyperkalemia Randomized Intervention Multi-Dose ZS-9 Maintenance Another; t.i.d. ¼ 3 times a day; ZS-9 ¼ sodium zirconium cyclosilicate; other abbreviations as in Tables 1 and 2 . Hyperkalemia in HF S a f e t y a n d t o l e r a b i l i t y . In the ZS-003 trial, the rates of adverse events were similar to those in the ZS-9 group (12.9%) and the placebo groups (10.8%), with diarrhea being the most common complication in both groups (1.7% in ZS-9 vs. 2.2% in placebo). In HARMONIZE, adverse events occurred in 53%, 29%, and 44% of patients receiving ZS-9 doses of 5, 10, and 15 g, respectively, compared with 32% in patients who received placebo. Edema was more common in the 15-g group. Gastrointestinal side effects were similar to those in the placebo group (14% placebo vs.
7%, 2%, and 9% for the 5-, 10-, and 15-g groups, respectively) (70).
EFFECT ON ALDOSTERONE
Renal hypoperfusion in HF activates the RAAS, which 
ONGOING TRIALS FOR PATIROMER AND ZS-9
The TOURMALINE (Patiromer With or Without Food for the Treatment of Hyperkalemia) study is an ongoing trial to determine patiromer's efficacy and safety when used once daily with or without food, focusing more on African American and Hispanic patients (NCT02694744) (80) . ZS-9 has an ongoing trial (ZS-005) to evaluate the safety and efficacy of 10 g 3 times a day for 24 to 72 h, followed by a long-term maintenance phase once daily for up to 12 months (NCT02163499) (81) .
FUTURE DIRECTION
According to HF guidelines, MRAs should not be used in patients with eGFR <30 ml/min or serum potassium levels >5.0 mmol/l (5, 6) . This leads to the exclusion of a significant group of HF patients (18% to 40%) with reduced ejection fraction who are not prescribed MRAs (82, 83) . Similarly, the use of ACEi or
ARBs is seen only in 55% to 63 % of patients with CKD in primary care; however, there is a lack of published data quantifying the role of hyperkalemia that results in lack of use of RAASi in this population (84) .
It is evident that there is a need for better therapies butler@stonybrookmedicine.edu.
